Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16232)	7/13/2003 10:17:30 PM
From: Cacaito	Respond to of 17367

Time pass by and I agree with you more. Look, the Fda gave Baxter the right to an "institutional consent" in bleeding subjects with a "blood substitute" that clearly could give hypertension and renal damage (and maybe strokes) to subjects and IT DID, and trial halted forever. Now, Northfield got the same privilege to use "institutional consent" in a "blood substitute" in bleeding subjects that could get "renal damage, hypertension and strokes" as the result of it, cause yes they are different polymerized Hb, but Hb !!! not much different among the Hbs cause they loss the ability to regulate blood vessels the way Rbc do. But, that the meningo trial did not obtain such a privilege is as much xoma failure as is Fda. History, now they are talking "acne", these guys are fresh to the max, or they do not believe bpi works.

To: Bluegreen who wrote (16232)	8/9/2003 9:17:10 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Bluegreen> I found your methotrexate quite interesting so I posted your idea to the Yahoo board. There is a excellent poster there that seems to know a lot about RA. Here is his reply to me. Comments here are welcome and encouraged> >The results of the hu1124 rheumatoid athritis trial were disappointing but not surprising since the antibody was used in combination with methotrexate. While some inhibitors of integrins (such as LFA-1) can show synergy with inhibitors that affect certain cellular pathways, in some instances just the opposite is true. This is especially the case given new insights regarding the unexpected effects of methotrexate on a signaling pathway known as Ras that can profundly affect integrins. Thus, it will require a more simplified clinical study uncomplicated by inhibitors of intersecting pathways to fully understand the utility of hu1124. It is likely that if Genentech/Xoma does not conduct such trials other companies developing antibody and small molecule inhibitors of integrins will do so. There is still a possibility that hu1124 will prove effective in this chronic T cell-mediated disease